Study Evaluating rhIL-11 in Left-Sided Ulcerative Colitis

Phase 1TerminatedNCT00038922

Wyeth is now a wholly owned subsidiary of Pfizer

Overview

To explore the safety of orally delivered rhIL-11 in patients with mild to moderate left-sided ulcerative colitis. To explore the effects of orally administered rhIL-11 on pharmacogenomics in blood samples and in colonic biopsy tissue samples.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Conditions

Ulcerative Colitis Inflammatory Bowel Disease

Interventions

rhIL-11DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Documented, signed informed consent to participate in this study * Age greater than or equal to 18 years * Documented diagnosis of ulcerative colitis by standard clinical criteria, including endoscopy (either flexible sigmoidoscopy or colonoscopy, sufficient to define the proximal limit of disease) with biopsy Exclusion Criteria: * Crohn's disease * Ulcerative proctitis * Ulcerative colitis extending beyond the splenic flexure

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.